Press Release
View printer-friendly version << Back
T2 Biosystems Announces New T2Sepsis Solution™ Clinical and Economic Results Presented by Leading Experts at ASM Microbe 2017 Conference

Clinical Experts Discuss T2BacteriaTM Early Experience and Potential Emergency Department Applications

T2Candida® Panel Users Present Compelling Rationale for Adoption, Implementation Process, and the Positive Clinical and Economic Results

LEXINGTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.(NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced new data on the company’s T2Sepsis Solution, which includes the T2Bacteria and T2Candida Panels, presented by clinical experts at the ASM Microbe 2017 conference in New Orleans, LA., on June 1-5. The T2Candida Panel is FDA-cleared and the T2Bacteria Panel is currently in clinical trials in the US and performance evaluations in the EU and is currently available for Research Use Only (RUO) in the US.

Dr. Cornelius Clancy, MD, Director of the Mycology Program and Chief of the Infectious Diseases Section at VA Pittsburgh Healthcare System, participated in “Debates in Medical Mycology” featuring the T2Candida Panel. “I was pleased to see that T2Candida has become a standard during any discussion regarding rapid diagnostics and antimicrobial stewardship,” said Dr. Clancy. “I believe that the hospitals using it are seeing strong value for their patients as well as better management of the drugs that lead to high resistance and costs.”

In the Science and Industry Showcase, “Managing Sepsis in the Golden Hour: Controlling Costs and Improving Patient Care through Diagnostic Testing,” Dr. Thomas Kirn, MD, PHD, Rutgers Robert Wood Johnson Medical School, and Dr. Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital, discussed the economic and clinical benefits of the T2Sepsis Solution’s direct-from-whole blood tests at their hospitals.

“With the T2Sepsis Solution, our hospital is not only reducing the use of antifungal therapy, we’re also identifying far more infected patients than was possible with blood culture,” said Dr. Edwards.

Dr. Edwards reported the following findings from Huntsville Hospital:

  • T2Candida detects more Candida infections, days faster than blood culture.
  • T2Candida provides superior sensitivity as compared to blood culture (94.4% vs. 28% sensitivity). Blood culture missed 26 confirmed Candida infections.
  • Negative T2Candida results led to cessation or no initiation of antifungal therapy in 64% of patients.
  • T2Candida improves hospital economics through de-escalation/non-initiation of unnecessary antifungals. T2Candida negative results decreased duration of micafungin by 2.1 days.

Dr. Thomas Kirn reported that Robert Wood Johnson Medical School is including the T2Candida Panel as a standard order in their sepsis protocol. Dr. Kirn reported that:

  • Negative T2Candida results led to cessation or no initiation of antifungal therapy in 67% of patients.
  • T2Candida would be most effective in standard, automated ordering practices.

Dr. Kirn also presented preliminary information about Robert Wood Johnson Medical School’s experience as part of the T2Bacteria pivotal trial. Dr. Kirn reported that initial data generated at their institution suggest that the T2Bacteria Panel may be identifying patients that would likely be missed by blood culture due to its insensitivity.

In the Science and Industry Showcase, “Application of Rapid, Blood Culture-Free Diagnostics in the Emergency Department: Improving the Signal to Noise Ratio,” Dr. Mitchell J. Cohen, M.D., Director of Surgery at the Denver Health and the University of Colorado School of Medicine, discussed the important role the T2Sepsis Solution may play in the emergency department.

“In the emergency department, rapid and precise results are critical to triage, treat, and make admission decisions in the best interest of the patient,” said Dr. Cohen. “The T2Sepsis Solution has the potential to provide the rapid results and high sensitivity necessary to make it a valuable tool for the management of infections that lead to sepsis in the ED.”

Dr. Cohen reported that T2Bacteria can be easily integrated in the emergency department setting due to its rapid turnaround time, while blood culture-reliant tests cannot.

“There was excitement and high quality, inbound interest from our target market during ASM Microbe 2017 Conference,” said John McDonough, president and chief executive officer. “There is growing evidence of improved patient care and hospital savings with T2Candida and market enthusiasm about T2Bacteria.”

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx®Instrument and T2Candida Panel targeting sepsis, a life-threatening infection, and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2MR technology to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2017, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer

Media Contact:
Matthew McKillip, T2

Investor Contact:
Tucker Elcock, Teneo Strategy

T2 Biosystems, Inc.